David Braun, MD, PhD, on the Unique Experiences at IKCS

Article

The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.

David Braun, MD, PhD, from Dana-Farber Cancer Institute, discussed the integration of fields and how they yield a unique experience at the International Kidney Cancer Symposium, held November 15-16, in Miami.

Transcription:
I mean, there’s a lot. I would say, so there’s incredibly interesting clinical work, there’s incredibly interesting scientific work. Honestly the most exciting thing for me has been the integration of everyone. Seeing people who are just master clinicians, people who are, you know, dedicated to their lab work and are pure scientists, people who are patient advocates who are obviously passionate and have personal experience, and seeing everyone in the same room together, I think that’s a unique experience. That’s really made this a special meeting.

Recent Videos
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content